VRTX
Vertex Pharmaceuticals Inc
NASDAQ: VRTX · HEALTHCARE · BIOTECHNOLOGY
$427.38
+0.98% today
Updated 2026-04-30
Market cap
$108.71B
P/E ratio
27.93
P/S ratio
9.06x
EPS (TTM)
$15.30
Dividend yield
—
52W range
$363 – $508
Volume
1.3M
Vertex Pharmaceuticals Inc (VRTX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
32.90%
Operating margin
39.60%
ROE
22.50%
ROA
12.20%
Debt/equity
0.21x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $216.36M | $-206.89M | 94.38% | -105.86% | -95.63% |
| 2007 | $199.01M | $-391.28M | 93.01% | -210.94% | -196.61% |
| 2008 | $175.50M | $-459.85M | 91.06% | -263.65% | -262.02% |
| 2009 | $102.05M | $-641.58M | 86.08% | -601.10% | -628.70% |
| 2010 | $143.37M | $-754.63M | 91.12% | -485.51% | -526.35% |
| 2011 | $1.41B | $29.57M | 94.29% | 8.07% | 2.10% |
| 2012 | $1.53B | $-107.03M | 81.67% | 0.15% | -7.01% |
| 2013 | $1.21B | $-445.03M | 89.25% | -74.54% | -36.72% |
| 2014 | $580.41M | $-738.55M | 89.49% | -119.30% | -127.25% |
| 2015 | $1.03B | $-558.12M | 87.84% | -45.40% | -54.06% |
| 2016 | $1.70B | $-112.05M | 87.64% | 0.58% | -6.58% |
| 2017 | $2.49B | $263.48M | 88.95% | 4.95% | 10.59% |
| 2018 | $3.05B | $2.10B | 86.56% | 20.84% | 68.80% |
| 2019 | $4.16B | $1.18B | 86.84% | 28.77% | 28.27% |
| 2020 | $6.21B | $2.71B | 88.14% | 46.03% | 43.70% |
| 2021 | $7.57B | $2.34B | 88.06% | 36.73% | 30.92% |
| 2022 | $8.93B | $3.32B | 87.90% | 48.23% | 37.20% |
| 2023 | $9.87B | $3.62B | 87.21% | 38.83% | 36.68% |
| 2024 | $11.02B | $-535.60M | 86.11% | -2.11% | -4.86% |
| 2025 | $12.07B | $3.95B | 85.03% | 39.43% | 32.74% |